Neurology

Cell culture studies suggest inhibiting NF-κB could help treat spinocerebellar ataxia type 17 (SCA17), which is caused by CAG/CAA repeat expansions in the TBP gene. In co-cultures of primary neurons and astrocytes from a genetic mouse model of SCA17, pretreatment of astrocytes with NF-κB inhibitor tool compounds decreased neurodegeneration in the neurons compared with no pretreatment. Next steps could include testing NF-κB inhibitors in SCA17 models.

Toyama Chemical Co. Ltd., Eisai Co. Ltd. and Taisho Pharmaceutical Holdings Co. Ltd. market Careram iguratimod, an NF-κB inhibitor, to treat rheumatoid arthritis...